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Abstract: Mucositis, also referred to as mucosal barrier
injury, is one of the most debilitating side effects of
radiotherapy and chemotherapy treatment. Clinically,
mucositis is associated with pain, bacteremia, and
malnutrition. Furthermore, mucositis is a frequent reason
to postpone chemotherapy treatment, ultimately leading
towards a higher mortality in cancer patients. According
to the model introduced by Sonis, both inflammation and
apoptosis of the mucosal barrier result in its discontinuity,
thereby promoting bacterial translocation. According to
this five-phase model, the intestinal microbiota plays no
role in the pathophysiology of mucositis. However,
research has implicated a prominent role for the
commensal intestinal microbiota in the development of
several inflammatory diseases like inflammatory bowel
disease, pouchitis, and radiotherapy-induced diarrhea.
Furthermore, chemotherapeutics have a detrimental
effect on the intestinal microbial composition (strongly
decreasing the numbers of anaerobic bacteria), coinciding
in time with the development of chemotherapy-induced
mucositis. We hypothesize that the commensal intestinal
microbiota might play a pivotal role in chemotherapy-
induced mucositis. In this review, we propose and discuss
five pathways in the development of mucositis that are
potentially influenced by the commensal intestinal
microbiota: 1) the inflammatory process and oxidative
stress, 2) intestinal permeability, 3) the composition of the
mucus layer, 4) the resistance to harmful stimuli and
epithelial repair mechanisms, and 5) the activation and
release of immune effector molecules. Via these pathways,
the commensal intestinal microbiota might influence all
phases in the Sonis model of the pathogenesis of
mucositis. Further research is needed to show the clinical
relevance of restoring dysbiosis, thereby possibly decreas-
ing the degree of intestinal mucositis.
Introduction
Mucositis, also referred to as mucosal barrier injury, is one of
the most debilitating side effects of radiotherapy and chemother-
apy treatment [1]. It is characterized by both inflammation and
cell loss in the epithelial barrier lining the gastrointestinal tract
[2,3]. Clinically, mucositis is associated with bacteremia, malnu-
trition, the use of total parenteral nutrition, and an increment in
the use of intravenous analgesics. These complications all lead to
longer hospitalizations and increasing health care costs. Moreover,
mucositis is a frequent reason for reducing the dosages of
chemotherapeutics or to postpone chemotherapy treatment,
ultimately leading towards a higher mortality in cancer patients
[2,4].
Historically, research has focused on oral mucositis. More
recently, attention has been drawn towards the pathophysiology
and clinical symptoms of intestinal mucositis, which is character-
ized by symptoms like nausea, bloating, vomiting, abdominal pain,
and severe diarrhea [5,6].
According to the model introduced by Sonis, five phases are
important in the pathophysiology of mucositis: (1) the formation of
reactive oxygen species leading to the activation of nuclear factor
kappa B (NFkB) during the initiation phase, (2) the induction of
messenger molecules such as tumor necrosis factor alpha (TNFa),
resulting in treatment-related tissue inflammation and apoptosis
during the upregulation/message generation phase, (3) the
amplification of messenger molecules in the amplification/
signaling phase, leading to more inflammation and apoptosis, (4)
discontinuity of the epithelial barrier resulting from apoptosis
during the ulcerative phase, thereby promoting bacterial translo-
cation, and (5) a spontaneous healing phase, characterized by cell
proliferation [3]. According to this five-phase model, the intestinal
microbiota plays no role in the pathophysiology of mucositis.
However, research has implicated a role for the commensal
intestinal microbiota in several local and systemic inflammatory
diseases like inflammatory bowel disease, pouchitis, radiotherapy-
induced diarrhea, atopic disease, obesity, and diabetes [7–11].
Recent studies have also shown that both chemotherapeutics and
(prophylactically used) antibiotics do have an effect on intestinal
microbial composition [12–14]. Moreover, the effects of the
changing commensal intestinal microbiota on the development
and severity of mucositis are being unravelled. Research has
shown that bacteria play a role in the metabolism of certain
chemotherapeutics. The outgrowth of these bacteria might lead to
the formation of active toxic metabolites of the chemotherapeutic
drug, which directly affects the progression of intestinal mucositis
[13]. However, the commensal intestinal microbiota might also
have beneficial effects on the development of intestinal mucositis,
as the mere presence of resident intestinal bacteria might offer
protection against its development. In this review, we propose and
discuss five pathways in the development of mucositis that are
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the inflammatory process and oxidative stress, 2) intestinal
permeability, 3) the composition of the mucus layer, 4) the
resistance towards harmful stimuli and epithelial repair mecha-
nisms, and 5) the activation and release of immune effector
molecules (Figures 1 and 2).
Host–Microbe Interaction
A detailed review of the communication pathways between the
intestinal microbiota and the human host is beyond the scope of
this article and this communication is therefore only shortly
reviewed.
The epithelial barrier lining the gastrointestinal tract is
composed of a single layer of epithelial cells intertwined by tight
junctions [15]. These epithelial cells have two important functions.
Firstly, they form a mechanical barrier separating the inside of the
human body from the outside world. Secondly, they are essential
in the communication between the human body and the intestinal
microbiota [16–18].
An important aspect of these two functions of the epithelial cells
is the dual mucus layer at the apical side of the epithelial cells
[19,20]. The inner layer strengthens the epithelial barrier, whereas
the loose outer layer is proposed to be important in the
communication between epithelial cells and microbiota [20,21].
With respect to the communication between microbes and the
gut, two groups of receptors are thought to be important in the
communication between the human body and the resident
microbiota: the Toll-like receptor (TLR) family and the nucleotide
oligomerisation domain (NOD) receptor family [22–25]. Both
groups of receptors play an important role in the genesis and
modulation of the inflammatory response. The TLRs are present
at the outer membrane of the epithelial cells. Bacteria are
recognized by the extracellularly located part of TLRs, leading to
activation of NFkB [23,25]. In turn, activation of NFkB results in
the development of an inflammatory response. So far, multiple
Figure 1. The epithelial barrier is comprised of a single layer of epithelial cells intertwined by tight junctions. The mechanical barrier is
increased further by a mucus layer. Binding of bacteria to TLRs present on epithelial cells results in the activation of NFkB, ultimately resulting in the
release of pro-inflammatory and anti-inflammatory cytokines. After phagocytosis, bacterial products are internalized and then are recognized by
receptors of the NOD family (NLRs), resulting in the modulation of the inflammatory response. Dendritic cells are capable of internalizing bacteria
sampled from the lumen, after which bacteria are presented to immune effector cells. HSPs, heat shock proteins; NLR, NOD-like receptor; sIgA,
secretory immunoglobulin A; TLR, Toll-like receptor.
doi:10.1371/journal.ppat.1000879.g001
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The most extensively researched receptors are TLR-2, TLR-3,
TLR-4, TLR-5, and TLR-9 [16,23,26–32]. TLR-2 is activated by
peptidoglycan, a part of the cell wall of gram-positive bacteria,
whereas TLR-4 is activated by lipopolysaccharide (LPS), a
substance of gram-negative microorganisms. TLR-3 is activated
by viral DNA, TLR-9 is activated by bacterial DNA, and TLR-5 is
activated by the protein flagellin, present in flagellated bacteria.
After binding to TLRs, bacteria are processed and bacterial parts
are transported intracellularly. Here they bind to receptors of the
NOD family. It is believed that activation of NOD receptors
modulates the inflammatory response activated by TLR binding
[22]. This theory is supported by the fact that NOD2/2 mice are
profoundly susceptible to intestinal inflammation [33,34]. More-
over, mutations in NOD2 are associated with the development of
Crohn’s disease in humans [35–37].
Not only epithelial cells, but also local dendritic cells are thought
to play a role in the initiation and/or modulation of intestinal
inflammation and, in addition, in the induction of tolerance [38–
40]. Dendritic cells sample bacteria from the intestinal lumen,
after which these bacteria are transported to the local lymph
nodes. Here, the bacteria are presented to immune cells, whose
activation can result in the activation of the innate and adaptive
immune system. Why certain microbial stimuli result in tolerance
where others induce an inflammatory response is still largely
unknown.
Pathways Describing the Role of Commensal
Intestinal Microbiota in Mucositis
1) Influencing the Inflammatory Process and Modulating
Oxidative Stress
The healthy human intestine is characterized by a state of low-
grade inflammation. The resident microbiota guarantees a constant
exposure to TLR ligands such as peptidoglycan, LPS, and bacterial
DNA. This ensures a continuous basal activation of downstream
signaling pathways, resulting in low-grade physiological inflamma-
tion [25,27]. Paradoxically, commensal bacteria are also capable of
suppressing more severe inflammatory responses, and their
disappearance may even result in incremental inflammation
[41–46]. For example, Bacteroides thetaiotaomicron and Bifidobacterium
infantis both decrease NFkB activation [43,47], leading to a decrease
in endotoxin levels and plasma interleukin (IL)-6 levels [45]. The
Clostridium XIVa group has been proposed to attenuate intestinal
inflammationby exerting an effect on polyaminesecretion,which in
turn regulates the expression of TLR-2 [28,48].
Figure 2. The resident microbiota interferes in the process of mucositis. Depicted are five possible ways in which intestinal bacteria can
attenuate or aggrevate mucositis: 1) influencing the inflammatory process, 2) influencing intestinal permeability, 3) influencing the composition of
the mucus layer, 4) influencing resistance to harmful stimuli and enhancing epithelial repair, and finally, 5) the activation and release of immune
effector molecules.
doi:10.1371/journal.ppat.1000879.g002
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relieve inflammatory symptoms. For example, Faecalibacterium
prausnitzii secretes a substance capable of decreasing NFkB
activation. This so far unidentified substance induces the
production of the anti-inflammatory IL-10, thereby attenuating
inflammation. B. infantis also secretes an unidentified product that
attenuates colitis in mice [46,49]. Several intestinal bacteria
produce short chain fatty acids (SCFAs), with butyrate being the
most thoroughly investigated. Butyrate is produced by F. prausnitzii
and Clostridium XIVa and has been shown to have profound anti-
inflammatory effects [50–54]. Substitution of butyrate attenuates
inflammatory symptoms in (diversion) colitis and chemotherapy-
induced mucositis in vivo in mice [46,55–58]. Moreover, butyrate
not only attenuates inflammation, but also reduces intestinal
permeability and stimulates the activation of immune effector
molecules.
In short, multiple intestinal bacteria are capable of decreasing
NFkB activation, resulting in a diminished production of
inflammatory cytokines. The exact nature and relevance of the
relationship between chemotherapy-induced mucositis, inflamma-
tion, and intestinal microbiota is subject to ongoing research.
2) Influencing Intestinal Permeability
Intestinal permeability increases after chemotherapy treatment,
and has been shown to be one of the hallmarks of the third and
fourth phases of mucositis as reported by Sonis [2,3,6]. One of the
mechanisms resulting in a chemotherapy-induced increase in
permeability is probably villous atrophy. Atrophy leads to an
increase of intestinal permeability, as has been shown both in vivo
and in vitro [59]. However, the resident intestinal microbiota has
also been proposed to influence intestinal permeability [26,60].
Indeed, several commensal bacteria have been shown to improve
the epithelial barrier function both in vitro and in vivo, although
not all in vivo studies were able to confirm these improvements
[59,61–65]. For example, TLR-2 ligands stimulate the phosphor-
ylation of protein kinase C, leading to a decrease in intestinal
permeability [26]. This decrease in permeability is proposed to be
the result of changes in tight junctions. Administration of
bifidobacteria is associated with an enhanced expression of
proteins forming tight junctions [49], and has been shown to
decrease intestinal permeability [64]. Both bifidobacteria and
lactobacilli have been shown to increase tight junction protein
expression and restore intestinal permeability [66–68].
Another factor contributing to attenuating intestinal permeabil-
ity is the bacterial induction of heat shock proteins (HSPs). These
HSPs are thought to preserve the viability of epithelial cells in
stress conditions [69–71], thereby reducing intestinal permeability.
Finally, the bacterial production of SCFAs is associated with a
reduction in intestinal permeability. This effect of SCFAs is also
proposed to be mediated by an increase in epithelial cell viability
[52,58,72].
Epithelial cell loss is a hallmark of the third phase of the five-
phase mucositis model, eventually resulting in an increased
permeability. The commensal intestinal microbiota attenuates
cellular atrophy and increases tight junction strength. Therefore,
we propose that changes in the commensal intestinal microbiota
influence the third phase of mucositis. This way, the commensal
intestinal microbiota might influence the eventual severity of
mucositis encountered in the ulcerative phase.
3) Influencing the Composition of the Mucus Layer
As mentioned before, the mucus layer covering the intestinal
epithelium strengthens the mechanical epithelial barrier. The
protective mucus layer is comprised of glycoproteins, trefoil
factors, and mucins. These mucins are produced by goblet cells,
which are specialized epithelial cells [73]. The composition of the
mucus layer is important in the protection against bacterial
infections and inflammation. For example, it has been shown that
mucin type 2 knockout mice develop severe colitis after harmful
stimuli, in contrast to mice capable of producing mucin 2.
Furthermore, in animals lacking mucin 2, bacteria are detected
deep down in the normally sterile crypts of the intestine [20,74].
The commensal intestinal microbiota is proposed to play a role
in the maintenance of the mucus layer. Indeed, the absence of
these intestinal microbiota is associated with a decrease in goblet
cells, which are also smaller in size [75]. Furthermore, the
thickness of the mucus layer is decreased in animals devoid of
intestinal microbiota.
The genes encoding mucins are directly regulated by bacteria
and their products [76–78], and in response to intestinal microbes
and/or their secreted products the secretion of mucus increases
[76,79]. For example, both Lactobacillus rhamnosus Gorbach and
Goldin (GG) and Lactobacillus plantarum increase the expression of
MUC-2 and MUC-3 genes, and Lactobacillus acidophilus upregulates
MUC-2 gene expression [77,80]. Furthermore, bacteria producing
butyrate are thought to play a role in the composition of the mucus
layer, as butyrate is capable of increasing mucin synthesis as well
[52].
The commensal resident microbiota not only interferes with the
expression of MUC genes, but also interferes with the expression
and/or activity of cell glycosyltransferases. These enzymes induce
changes in the carbohydrate repertoire of mucins, which might
change their efficacy in bacterial defense [81,82].
Thus, the intestinal microbiota influences the composition of the
mucus layer covering the epithelium, thereby increasing the
strength of the epithelial barrier. A strengthened barrier decreases
the risk of bacterial translocation, thereby possibly attenuating
inflammation present in the ulcerative phase of the Sonis mucositis
model.
4) Influencing Resistance to Harmful Stimuli and
Influencing Epithelial Repair
The commensal intestinal microbiota contributes to epithelial
repair. In germ-free animals, the mitotic index and cell turnover of
epithelial cells are lower as compared to normally colonized
animals [83,84]. Moreover, the transit time of epithelial cells
migrating towards the top of the intestinal villi is prolonged [85].
These changes result in a retarded renewal, i.e., a retarded repair,
of the intestinal epithelium.
Bacterial induction of NFkB not only controls the physiological
state of low-grade inflammation in the intestine, it also stimulates
the repair of, for example, mechanical-induced epithelial damage
[86]. The importance of bacterial ligands in this process is shown
in TLR-42/2 epithelial cells. These cells, which are not capable
of recognizing the resident microbiota, exhibit severe repair
defects in response to harmful chemical stimuli. This is probably
due to a reduced capacity of NFkB-induced cytoprotective factors
such as HSPs and IL-6 [25,29]. When TLR ligands were
administered to germ-free mice, this was sufficient to protect
them against artificially induced colitis [25].
Bacteria acting as TLR ligands are not the only ones that play
an important role in increasing the resistance towards harmful
stimuli and enhancing epithelial repair. Again, butyrate plays an
important role. Butyrate stimulates the migration of epithelial cells,
thereby enhancing mucosal healing [52,72]. Other bacterial
products, such as the peptides secreted by L. rhamnosus GG, have
been shown to inhibit cytokine-induced apoptosis and promote cell
growth, thereby also enhancing mucosal repair [87].
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microbiota might attenuate the epithelial damage in the third
phase of mucositis. As the commensal intestinal microbiota
stimulates epithelial repair mechanisms, it can be hypothesized
that the microbiota also attenuates mucositis by influencing the
healing phase of mucositis.
5) Influencing the Production and Release of Immune
Effector Molecules
The commensal intestinal microbiota regulates the expression
and release of immune effector molecules. These molecules are
pivotal for maintaining intestinal homeostasis [27,88–90]. For
example, if the contact between microbiota and intestinal
epithelium suddenly increases, the expression of RegIIIc increases.
This C-type lectin has antimicrobial activity and limits bacterial
translocation. Furthermore, it maintains intestinal integrity and
homeostasis [89,90].
Another immune effector molecule influenced by the resident
microbiota is immunoglobulin A (IgA). IgA is produced by
mucosa-associated immune effector cells [81,90,91]. Intestinal
microbiota is capable of regulating the expression of IgA, which in
turn regulates the composition of the intestinal microbiota. For
example, suppletion of bifidobacteria is associated with an increase
in the expression of secretory IgA [92].
Both live bacteria and their products are capable of upregulat-
ing immune effector molecules. For example, SCFAs such as
butyrate regulate the production of cathelicidins, which exhibit
broad-spectrum anti-bacterial activity against potential pathogens
[93].
By influencing the expression and release of immune effector
molecules, the commensal intestinal microbiota regulates itself and
maintains homeostasis in the intestinal tract. In the end, this will
positively influence all five phases described in Sonis’s mucositis
model.
Conclusion; an Extended Five-Phase Model for
Mucositis
Although the protective role of commensal intestinal bacteria in
human disease is increasingly being appreciated, research
concerning the relationship between intestinal bacteria and
chemotherapy-induced mucositis is still scarce. Most studies that
investigate the role of bacteria in human disease have focused on
inflammatory bowel disease, which is caused by a chronic
inflammatory process instead of the acute damage induced by
chemotherapeutics.
In the model introduced by Sonis to explain the pathogenesis of
radiotherapy-induced and chemotherapy-induced mucositis, the
resident intestinal microbiota played no role [3]. However,
recently it has been shown that chemotherapy treatment is
associated with a decrease in the number of anaerobic bacteria
and a decrease in microbial diversity [14,94]. Furthermore, the
resident intestinal bacteria have been shown to play a role in
radiotherapy-induced diarrhea [10]. Moreover, research has
shown that a decreasing microbial diversity coincides in time with
the development of severe chemotherapy-induced mucositis (M.
van Vliet et al., unpublished data). We hypothesize that the
commensal intestinal microbiota might play a pivotal role in both
radiotherapy-induced and chemotherapy-induced mucositis when
the intestine is irradiated or when chemotherapeutics are used that
deregulate intestinal microbial homeostasis, as the disappearance
of the intestinal microbiota will minimize their protection of
enterocytes against harmful stimuli. Further research is needed to
show whether the commensal intestinal bacteria should be
incorporated as a meaningful factor in Sonis’s five-phase model
for mucositis. Theoretically, the commensal intestinal microbiota
could influence all phases of the pathogenesis of mucositis: the
initiation phase, the phase of upregulation and message genera-
tion, the phase of amplification and signalling, the ulcerative
phase, and the healing phase.
Further research will also have to show the clinical relevance of
restoring dysbiosis, thereby possibly decreasing the degree of
intestinal mucositis. This would not only increase the quality of life
of patients, but could also positively influence treatment intensity,
probably decreasing the morbidity and mortality of cancer
patients. Completely restoring dysbiosis might be a clinical
problem, since whole live bacteria used as probiotics have already
been described as causing invasive infections in immunocompro-
mised patients and were associated with increased mortality in
patients with severe pancreatitis [95–98]. However, it has been
shown that substitution of bacterial parts instead of whole live
bacteria might be sufficient to attenuate local and systemic
inflammation without the risk of invasive infections [30,99,100].
References
1. Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ (2000) Patient reports
of complications of bone marrow transplantation. Support Care Cancer 8: 33–
39.
2. Blijlevens NM, Donnelly JP, De Pauw BE (2000) Mucosal barrier injury:
biology, pathology, clinical counterparts and consequences of intensive
treatment for haematological malignancy: an overview. Bone Marrow
Transplant 25: 1269–1278.
3. Sonis ST (2004) The pathobiology of mucositis. Nat Rev Cancer 4: 277–284.
4. Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, et al. (2001) Oral mucositis
and the clinical and economic outcomes of hematopoietic stem-cell transplan-
tation. J Clin Oncol 19: 2201–2205.
5. Blijlevens NM, Donnelly JP, DePauw BE (2005) Inflammatory response to
mucosal barrier injury after myeloablative therapy in allogeneic stem cell
transplant recipients. Bone Marrow Transplant 36: 703–707.
6. Lutgens LC, Blijlevens NM, Deutz NE, Donnelly JP, Lambin P, et al. (2005)
Monitoring myeloablative therapy-induced small bowel toxicity by serum
citrulline concentration: a comparison with sugar permeability tests. Cancer 103:
191–199.
7. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, et al. (2008) Changes in
gut microbiota control metabolic endotoxemia-induced inflammation in high-fat
diet-induced obesity and diabetes in mice. Diabetes 57: 1470–1481.
8. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, et al. (2007)
Molecular-phylogenetic characterization of microbial community imbalances in
human inflammatory bowel diseases. Proc Natl Acad Sci U S A 104:
13780–13785.
9. Gosselink MP, Schouten WR, van Lieshout LM, Hop WC, Laman JD, et al.
(2004) Eradication of pathogenic bacteria and restoration of normal pouch flora:
comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. Dis
Colon Rectum 47: 1519–1525.
10. Manichanh C, Varela E, Martinez C, Antolin M, Llopis M, et al. (2008) The gut
microbiota predispose to the pathophysiology of acute postradiotherapy
diarrhea. Am J Gastroenterol 103: 1754–1761.
11. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, et al. (2006) An
obesity-associated gut microbiome with increased capacity for energy harvest.
Nature 444: 1027–1031.
12. Edlund C, Nord CE (2000) Effect on the human normal microflora of oral
antibiotics for treatment of urinary tract infections. J Antimicrob Chemother 46
Suppl 1: 41–48.
13. Stringer AM, Gibson RJ, Bowen JM, Logan RM, Ashton K, et al. (2009)
Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an
amended intestinal flora and mucin profile. Int J Exp Pathol 90: 489–499.
14. van Vliet MJ, Tissing WJ, Dun CA, Meessen NE, Kamps WA, et al. (2009)
Chemotherapy treatment in pediatric patients with acute myeloid leukemia
receiving antimicrobial prophylaxis leads to a relative increase of colonization
with potentially pathogenic bacteria in the gut. Clin Infect Dis 49: 262–270.
15. Powell DW (1981) Barrier function of epithelia. Am J Physiol 241: G275–G288.
16. Cario E (2005) Bacterial interactions with cells of the intestinal mucosa: Toll-like
receptors and NOD2. Gut 54: 1182–1193.
17. Medzhitov R (2007) Recognition of microorganisms and activation of the
immune response. Nature 449: 819–826.
PLoS Pathogens | www.plospathogens.org 5 May 2010 | Volume 6 | Issue 5 | e100087918. Sartor RB (2008) Microbial influences in inflammatory bowel diseases.
Gastroenterology 134: 577–594.
19. Atuma C, Strugala V, Allen A, Holm L (2001) The adherent gastrointestinal
mucus gel layer: thickness and physical state in vivo. Am J Physiol Gastrointest
Liver Physiol 280: G922–G929.
20. Johansson ME, Phillipson M, Petersson J, Velcich A, Holm L, et al. (2008) The
inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of
bacteria. Proc Natl Acad Sci U S A 105: 15064–15069.
21. Swidsinski A, Loening-Baucke V, Theissig F, Engelhardt H, Bengmark S, et al.
(2007) Comparative study of the intestinal mucus barrier in normal and inflamed
colon. Gut 56: 343–350.
22. Constans A (2005) Giving a nod2 the right target. The scientist 19: 24–25.
23. Doyle SL, O’Neill LA (2006) Toll-like receptors: from the discovery of
NFkappaB to new insights into transcriptional regulations in innate immunity.
Biochem Pharmacol 72: 1102–1113.
24. Franchi L, Warner N, Viani K, Nunez G (2009) Function of Nod-like receptors
in microbial recognition and host defense. Immunol Rev 227: 106–128.
25. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R
(2004) Recognition of commensal microflora by toll-like receptors is required for
intestinal homeostasis. Cell 118: 229–241.
26. Cario E, Gerken G, Podolsky DK (2004) Toll-like receptor 2 enhances ZO-1-
associated intestinal epithelial barrier integrity via protein kinase C. Gastroen-
terology 127: 224–238.
27. Cario E (2008) Therapeutic impact of toll-like receptors on inflammatory bowel
diseases: a multiple-edged sword. Inflamm Bowel Dis 14: 411–421.
28. Chen J, Rao JN, Zou T, Liu L, Marasa BS, et al. (2007) Polyamines are required
for expression of Toll-like receptor 2 modulating intestinal epithelial barrier
integrity. Am J Physiol Gastrointest Liver Physiol 293: G568–G576.
29. Fukata M, Michelsen KS, Eri R, Thomas LS, Hu B, et al. (2005) Toll-like
receptor-4 is required for intestinal response to epithelial injury and limiting
bacterial translocation in a murine model of acute colitis. Am J Physiol
Gastrointest Liver Physiol 288: G1055–G1065.
30. Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, et al. (2004)
Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics
in murine experimental colitis. Gastroenterology 126: 520–528.
31. Vicente-Suarez I, Takahashi Y, Cheng F, Horna P, Wang HW, et al. (2007)
Identification of a novel negative role of flagellin in regulating IL-10 production.
Eur J Immunol 37: 3164–3175.
32. Vijay-Kumar M, Wu H, Aitken J, Kolachala VL, Neish AS, et al. (2007)
Activation of toll-like receptor 3 protects against DSS-induced acute colitis.
Inflamm Bowel Dis 13: 856–864.
33. Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, et al. (2005)
Nod2-dependent regulation of innate and adaptive immunity in the intestinal
tract. Science 307: 731–734.
34. Watanabe T, Kitani A, Murray PJ, Wakatsuki Y, Fuss IJ, et al. (2006) Nucleotide
binding oligomerization domain 2 deficiency leads to dysregulated TLR2
signaling and induction of antigen-specific colitis. Immunity 25: 473–485.
35. Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, et al. (2001)
Association between insertion mutation in NOD2 gene and Crohn’s disease in
German and British populations. Lancet 357: 1925–1928.
36. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, et al. (2001)
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s
disease. Nature 411: 599–603.
37. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, et al. (2001) A
frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease.
Nature 411: 603–606.
3 8 .B j o r c kP ,B e i l h a c kA ,H e r m a nE I ,N e g r i nR S ,E n g l e m a nE G( 2 0 0 8 )
Plasmacytoid dendritic cells take up opsonized antigen leading to CD4+ and
CD8+ T cell activation in vivo. J Immunol 181: 3811–3817.
39. Hapfelmeier S, Muller AJ, Stecher B, Kaiser P, Barthel M, et al. (2008) Microbe
sampling by mucosal dendritic cells is a discrete, MyD88-independent step in
DeltainvG S. Typhimurium colitis. J Exp Med 205: 437–450.
40. Niess JH, Reinecker HC (2006) Dendritic cells in the recognition of intestinal
microbiota. Cell Microbiol 8: 558–564.
41. Borody TJ, Warren EF, Leis S, Surace R, Ashman O (2003) Treatment of
ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 37: 42–47.
42. Frick JS, Schenk K, Quitadamo M, Kahl F, Koberle M, et al. (2007)
Lactobacillus fermentum attenuates the proinflammatory effect of Yersinia
enterocolitica on human epithelial cells. Inflamm Bowel Dis 13: 83–90.
43. Kelly D, Campbell JI, King TP, Grant G, Jansson EA, et al. (2004) Commensal
anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplas-
mic shuttling of PPAR-gamma and RelA. Nat Immunol 5: 104–112.
44. Khan MA, Ma C, Knodler LA, Valdez Y, Rosenberger CM, et al. (2006) Toll-
like receptor 4 contributes to colitis development but not to host defense during
Citrobacter rodentium infection in mice. Infect Immun 74: 2522–2536.
45. O’Hara AM, O’Regan P, Fanning A, O’Mahony C, Macsharry J, et al. (2006)
Functional modulation of human intest i n a le p i t h e l i a lc e l lr e s p o n s e sb y
Bifidobacterium infantis and Lactobacillus salivarius. Immunology 118:
202–215.
46. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, et al.
(2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal
bacterium identified by gut microbiota analysis of Crohn disease patients. Proc
Natl Acad Sci U S A 105: 16731–16736.
47. Beg AA (2004) ComPPARtmentalizing NF-kappaB in the gut. Nat Immunol 5:
14–16.
48. Matsumoto M, Benno Y (2007) The relationship between microbiota and
polyamine concentration in the human intestine: a pilot study. Microbiol
Immunol 51: 25–35.
49. Ewaschuk JB, Diaz H, Meddings L, Diederichs B, Dmytrash A, et al. (2008)
Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell
barrier function. Am J Physiol Gastrointest Liver Physiol 295: G1025–G1034.
50. Barcenilla A, Pryde SE, Martin JC, Duncan SH, Stewart CS, et al. (2000)
Phylogenetic relationships of butyrate-producing bacteria from the human gut.
Appl Environ Microbiol 66: 1654–1661.
51. Duncan SH, Hold GL, Harmsen HJ, Stewart CS, Flint HJ (2002) Growth
requirements and fermentation products of Fusobacterium prausnitzii, and a
proposal to reclassify it as Faecalibacterium prausnitzii gen. nov., comb. nov.
Int J Syst Evol Microbiol 52: 2141–2146.
52. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, et al. (2008)
Review article: the role of butyrate on colonic function. Aliment Pharmacol
Ther 27: 104–119.
53. Hamer HM, Jonkers DM, Bast A, Vanhoutvin SA, Fischer MA, et al. (2008)
Butyrate modulates oxidative stress in the colonic mucosa of healthy humans.
Clin Nutr.
54. Nancey S, Bienvenu J, Coffin B, Andre F, Descos L, et al. (2002) Butyrate
strongly inhibits in vitro stimulated release of cytokines in blood. Dig Dis Sci 47:
921–928.
55. Di Sabatino A, Morera R, Ciccocioppo R, Cazzola P, Gotti S, et al. (2005) Oral
butyrate for mildly to moderately active Crohn’s disease. Aliment Pharmacol
Ther 22: 789–794.
56. Harig JM, Soergel KH, Komorowski RA, Wood CM (1989) Treatment of
diversion colitis with short-chain-fatty acid irrigation. N Engl J Med 320: 23–28.
57. Ramos MG, Bambirra EA, Cara DC, Vieira EC, Alvarez-Leite JI (1997) Oral
administration of short-chain fatty acids reduces the intestinal mucositis caused
by treatment with Ara-C in mice fed commercial or elemental diets. Nutr
Cancer 28: 212–217.
58. Venkatraman A, Ramakrishna BS, Shaji RV, Kumar NS, Pulimood A, et al.
(2003) Amelioration of dextran sulfate colitis by butyrate: role of heat shock
protein 70 and NF-kappaB. Am J Physiol Gastrointest Liver Physiol 285:
G177–G184.
59. Wang Q, Wang XD, Jeppsson B, Andersson R, Karlsson B, et al. (1996)
Influence of colostomy on in vivo and in vitro permeability of the rat colon. Dis
Colon Rectum 39: 663–670.
60. Samonte VA, Goto M, Ravindranath TM, Fazal N, Holloway VM, et al. (2004)
Exacerbation of intestinal permeability in rats after a two-hit injury: burn and
Enterococcus faecalis infection. Crit Care Med 32: 2267–2273.
61. Eutamene H, Lamine F, Chabo C, Theodorou V, Rochat F, et al. (2007)
Synergy between Lactobacillus paracasei and its bacterial products to counteract
stress-induced gut permeability and sensitivity increase in rats. J Nutr 137:
1901–1907.
62. Heyman M, Terpend K, Menard S (2005) Effects of specific lactic acid bacteria
on the intestinal permeability to macromolecules and the inflammatory
condition. Acta Paediatr Suppl 94: 34–36.
63. Qin HL, Zheng JJ, Tong DN, Chen WX, Fan XB, et al. (2008) Effect of
Lactobacillus plantarum enteral feeding on the gut permeability and septic
complications in the patients with acute pancreatitis. Eur J Clin Nutr 62:
923–930.
64. Stratiki Z, Costalos C, Sevastiadou S, Kastanidou O, Skouroliakou M, et al.
(2007) The effect of a bifidobacter supplemented bovine milk on intestinal
permeability of preterm infants. Early Hum Dev 83: 575–579.
65. Zeng J, Li YQ, Zuo XL, Zhen YB, Yang J, et al. (2008) Clinical trial: effect of
active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-
predominant irritable bowel syndrome. Aliment Pharmacol Ther 28: 994–1002.
66. Liu Q, Nobaek S, Adawi D, Mao Y, Wang M, et al. (2001) Administration of
Lactobacillus plantarum 299v reduces side-effects of external radiation on colon
anastomotic healing in an experimental model. Colorectal Dis 3: 245–252.
67. Qin HL, Shen TY, Gao ZG, Fan XB, Hang XM, et al. (2005) Effect of
lactobacillus on the gut microflora and barrier function of the rats with
abdominal infection. World J Gastroenterol 11: 2591–2596.
68. Moorthy G, Murali MR, Devaraj SN (2008) Lactobacilli facilitate maintenance
of intestinal membrane integrity during Shigella dysenteriae 1 infection in rats.
Nutrition.
69. Aijaz S, Sanchez-Heras E, Balda MS, Matter K (2007) Regulation of tight
junction assembly and epithelial morphogenesis by the heat shock protein Apg-2.
BMC Cell Biol 8: 49.
70. Arvans DL, Vavricka SR, Ren H, Musch MW, Kang L, et al. (2005) Luminal
bacterial flora determines physiological expression of intestinal epithelial
cytoprotective heat shock proteins 25 and 72. Am J Physiol Gastrointest Liver
Physiol 288: G696–G704.
71. Matsuo K, Zhang X, Ono Y, Nagatomi R (2009) Acute stress-induced colonic
tissue HSP70 expression requires commensal bacterial components and intrinsic
glucocorticoid. Brain Behav Immun 23: 108–115.
72. Venkatraman A, Ramakrishna BS, Pulimood AB (1999) Butyrate hastens
restoration of barrier function after thermal and detergent injury to rat distal
colon in vitro. Scand J Gastroenterol 34: 1087–1092.
PLoS Pathogens | www.plospathogens.org 6 May 2010 | Volume 6 | Issue 5 | e100087973. Moncada DM, Kammanadiminti SJ, Chadee K (2003) Mucin and Toll-like
receptors in host defense against intestinal parasites. Trends Parasitol 19:
305–311.
74. Van der Sluis M, De Koning BA, De Bruijn AC, Velcich A, Meijerink JP, et al.
(2006) Muc2-deficient mice spontaneously develop colitis, indicating that MUC2
is critical for colonic protection. Gastroenterology 131: 117–129.
75. Kandori H, Hirayama K, Takeda M, Doi K (1996) Histochemical, lectin-
histochemical and morphometrical characteristics of intestinal goblet cells of
germfree and conventional mice. Exp Anim 45: 155–160.
76. Caballero-Franco C, Keller K, De Simone C, Chadee K (2007) The VSL#3
probiotic formula induces mucin gene expression and secretion in colonic
epithelial cells. Am J Physiol Gastrointest Liver Physiol 292: G315–G322.
77. Kim Y, Kim SH, Whang KY, Kim YJ, Oh S (2008) Inhibition of Escherichia
coli O157:H7 attachment by interactions between lactic acid bacteria and
intestinal epithelial cells. J Microbiol Biotechnol 18: 1278–1285.
78. Mattar AF, Teitelbaum DH, Drongowski RA, Yongyi F, Harmon CM, et al.
(2002) Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell-
culture model. Pediatr Surg Int 18: 586–590.
79. Barcelo A, Claustre J, Moro F, Chayvialle JA, Cuber JC, et al. (2000) Mucin
secretion is modulated by luminal factors in the isolated vascularly perfused rat
colon. Gut 46: 218–224.
80. Mack DR, Ahrne S, Hyde L, Wei S, Hollingsworth MA (2003) Extracellular
MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal
epithelial cells in vitro. Gut 52: 827–833.
81. Bourlioux P, Koletzko B, Guarner F, Braesco V (2003) The intestine and its
microflora are partners for the protection of the host: report on the Danone
Symposium ‘‘The Intelligent Intestine,’’ held in Paris, June 14, 2002. Am J Clin
Nutr 78: 675–683.
82. Hooper LV, Gordon JI (2001) Commensal host-bacterial relationships in the
gut. Science 292: 1115–1118.
83. Rolls BA, Turvey A, Coates ME (1978) The influence of the gut microflora and
of dietary fibre on epithelial cell migration in the chick intestine. Br J Nutr 39:
91–98.
84. Webb P, Chanana AD, Cronkite EP, Laissue JA, Joel DD (1980) Comparison of
DNA renewal in germ-free and conventional mice using [125I]iododeoxyuridine
and [3H]thymidine. Cell Tissue Kinet 13: 227–237.
85. Savage DC, Siegel JE, Snellen JE, Whitt DD (1981) Transit time of epithelial
cells in the small intestines of germfree mice and ex-germfree mice associated
with indigenous microorganisms. Appl Environ Microbiol 42: 996–1001.
86. Karrasch T, Steinbrecher KA, Allard B, Baldwin AS, Jobin C (2006) Wound-
induced p38MAPK-dependent histone H3 phosphorylation correlates with
increased COX-2 expression in enterocytes. J Cell Physiol 207: 809–815.
87. Yan F, Cao H, Cover TL, Whitehead R, Washington MK, et al. (2007) Soluble
proteins produced by probiotic bacteria regulate intestinal epithelial cell survival
and growth. Gastroenterology 132: 562–575.
88. Ayabe T, Satchell DP, Wilson CL, Parks WC, Selsted ME, et al. (2000)
Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to
bacteria. Nat Immunol 1: 113–118.
89. Cash HL, Whitham CV, Behrendt CL, Hooper LV (2006) Symbiotic bacteria
direct expression of an intestinal bactericidal lectin. Science 313: 1126–1130.
90. Strober W (2006) Immunology. Unraveling gut inflammation. Science 313:
1052–1054.
91. Di Giacinto C, Marinaro M, Sanchez M, Strober W, Boirivant M (2005)
Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10
and IL-10-dependent TGF-beta-bearing regulatory cells. J Immunol 174:
3237–3246.
92. Wang Z, Xiao G, Yao Y, Guo S, Lu K, et al. (2006) The role of bifidobacteria in
gut barrier function after thermal injury in rats. J Trauma 61: 650–657.
93. Muller CA, Autenrieth IB, Peschel A (2005) Innate defenses of the intestinal
epithelial barrier. Cell Mol Life Sci 62: 1297–1307.
94. Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, et al. (2009)
Gastrointestinal microflora and mucins may play a critical role in the
development of 5-Fluorouracil-induced gastrointestinal mucositis. Exp Biol
Med (Maywood) 234: 430–441.
95. Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H,
et al. (2008) Probiotic prophylaxis in predicted severe acute pancreatitis: a
randomised, double-blind, placebo-controlled trial. Lancet 371: 651–659.
96. Cannon JP, Lee TA, Bolanos JT, Danziger LH (2005) Pathogenic relevance of
Lactobacillus: a retrospective review of over 200 cases. Eur J Clin Microbiol
Infect Dis 24: 31–40.
97. Ledoux D, Labombardi VJ, Karter D (2006) Lactobacillus acidophilus
bacteraemia after use of a probiotic in a patient with AIDS and Hodgkin’s
disease. Int J STD AIDS 17: 280–282.
98. Liong MT (2008) Safety of probiotics: translocation and infection. Nutr Rev 66:
192–202.
99. Katakura K, Lee J, Rachmilewitz D, Li G, Eckmann L, et al. (2005) Toll-like
receptor 9-induced type I IFN protects mice from experimental colitis. J Clin
Invest 115: 695–702.
100. Rachmilewitz D, Karmeli F, Takabayashi K, Hayashi T, Leider-Trejo L, et al.
(2002) Immunostimulatory DNA ameliorates experimental and spontaneous
murine colitis. Gastroenterology 122: 1428–1441.
PLoS Pathogens | www.plospathogens.org 7 May 2010 | Volume 6 | Issue 5 | e1000879